Monopar Therapeutics (MNPR) Other Operating Expenses (2017 - 2025)
Monopar Therapeutics (MNPR) posted Other Operating Expenses of -$1.0 for Q3 2025, down 100.0% sequentially from $14.5 million in Q3 2017.
Monopar Therapeutics (MNPR) Other Operating Expenses (2017 - 2025) Analysis & Trends
Monopar Therapeutics has reported Other Operating Expenses for 2 years, with the latest figure at -$1.0 in Q3 2025.
- Quarterly Other Operating Expenses changed N/A year-over-year to -$1.0 in Q3 2025, while the trailing twelve-month figure through Dec 2025 was -$1.0 (changed N/A YoY) and the FY2017 annual result came in at $14.5 million, changed N/A from the prior year.
- Other Operating Expenses slipped to -$1.0 in Q3 2025 per MNPR's latest filing, from $14.5 million in the prior quarter.
- Over five years, Other Operating Expenses peaked at -$1.0 in Q3 2025 and troughed at -$1.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.00 |
| Sep 30, 2017 | 14.50 Mn |